-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Enlivex Therapeutics Ltd. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2023 to Q2 2024.
- Enlivex Therapeutics Ltd. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $388K, a 24.1% decline year-over-year.
- Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2023 was $1.95M, a 28.1% decline from 2022.
- Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2022 was $2.71M, a 6.93% decline from 2021.
- Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2021 was $2.91M, a 116% increase from 2020.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)